MARKET

ADVM

ADVM

Adverum Biotech
NASDAQ
0.6880
-0.0040
-0.58%
After Hours: 0.6688 -0.0192 -2.79% 16:07 02/07 EST
OPEN
0.6909
PREV CLOSE
0.6920
HIGH
0.7100
LOW
0.6804
VOLUME
26.64K
TURNOVER
0
52 WEEK HIGH
1.820
52 WEEK LOW
0.5310
MARKET CAP
68.61M
P/E (TTM)
-0.4354
1D
5D
1M
3M
1Y
5Y
4D Molecular Therapeutics: Another Gene Therapy Player With A Differentiated Profile
Seeking Alpha · 01/03 13:55
BRIEF-Adverum Biotechnologies Inc Says Linda Rubinstein Appointed CFO
Reuters · 12/13/2022 15:11
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 11/28/2022 21:32
BRIEF-Adverum Biotechnologies Inc - On November 18, Co Received Notice Of Delisting From Nasdaq
Reuters · 11/25/2022 11:06
Chardan Capital Maintains Neutral on Adverum Biotechnologies, Lowers Price Target to $2
Benzinga · 11/11/2022 13:23
RBC Capital Maintains Sector Perform on Adverum Biotechnologies, Lowers Price Target to $3
Benzinga · 11/11/2022 13:06
--RBC Cuts Price Target on Adverum Biotechnologies to $3 From $5, Maintains Sector Perform, Speculative Risk
--RBC Cuts Price Target on Adverum Biotechnologies to $3 From $5, Maintains Sector Perform, Speculative Risk
MT Newswires · 11/11/2022 08:07
--Chardan Trims Price Target on Adverum Biotechnologies to $2 From $2.50, Retains Neutral Rating
--Chardan Trims Price Target on Adverum Biotechnologies to $2 From $2.50, Retains Neutral Rating
MT Newswires · 11/11/2022 07:13
More
About ADVM
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company, which targets unmet medical needs in ocular and rare diseases. The Company develops gene therapy product candidates. Its lead product candidate, ADVM-022, is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. ADVM-022 is being developed for the treatment of patients with wet age-related macular degeneration (wet AMD) who are responsive to anti-VEGF therapy. The Company's second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy (BCM) via a single IVT injection.

Webull offers kinds of Adverum Biotechnologies Inc stock information, including NASDAQ:ADVM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADVM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADVM stock methods without spending real money on the virtual paper trading platform.